145 Progression-free survival (PFS) in the EDP-M arm was also significantly longer at 5 months versus 2 months in the SZ-M arm, and there was a suggestion of better OS in the former group (14.8 months for EDP-M versus 12 months for SZ-M), although this did not reach statistical significance, possibly due to the cross-over design of the trial.
← all excerpts
Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment.
1
—
—